Sequoia Financial Advisors LLC Acquires 13,068 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Sequoia Financial Advisors LLC lifted its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 1,256.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 14,108 shares of the medical research company's stock after buying an additional 13,068 shares during the period. Sequoia Financial Advisors LLC's holdings in Charles River Laboratories International were worth $3,335,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. VisionPoint Advisory Group LLC lifted its stake in Charles River Laboratories International by 105.7% during the third quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company's stock worth $28,000 after purchasing an additional 74 shares during the period. Headlands Technologies LLC acquired a new stake in shares of Charles River Laboratories International during the third quarter worth approximately $37,000. Operose Advisors LLC acquired a new stake in shares of Charles River Laboratories International during the third quarter worth approximately $42,000. Covestor Ltd increased its holdings in shares of Charles River Laboratories International by 100.0% during the first quarter. Covestor Ltd now owns 174 shares of the medical research company's stock worth $49,000 after buying an additional 87 shares in the last quarter. Finally, Venturi Wealth Management LLC increased its holdings in shares of Charles River Laboratories International by 74.7% during the third quarter. Venturi Wealth Management LLC now owns 262 shares of the medical research company's stock worth $51,000 after buying an additional 112 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on CRL. TheStreet raised shares of Charles River Laboratories International from a "c+" rating to a "b-" rating in a report on Friday, March 1st. Argus lifted their target price on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the stock a "buy" rating in a report on Monday, March 18th. Robert W. Baird lifted their target price on shares of Charles River Laboratories International from $252.00 to $268.00 and gave the stock an "outperform" rating in a report on Thursday, February 15th. JPMorgan Chase & Co. lifted their price target on shares of Charles River Laboratories International from $270.00 to $280.00 and gave the stock an "overweight" rating in a research report on Thursday, February 15th. Finally, Citigroup lifted their price target on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the stock a "neutral" rating in a research report on Thursday, February 15th. Five analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $253.23.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Shannon M. Parisotto sold 5,882 shares of the stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the sale, the executive vice president now directly owns 2,596 shares in the company, valued at $626,155.20. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, EVP Shannon M. Parisotto sold 5,882 shares of Charles River Laboratories International stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the transaction, the executive vice president now owns 2,596 shares of the company's stock, valued at $626,155.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP William D. Barbo sold 4,050 shares of Charles River Laboratories International stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the completion of the sale, the vice president now directly owns 22,879 shares of the company's stock, valued at $5,685,431.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 14,932 shares of company stock worth $3,693,663. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Price Performance

Shares of Charles River Laboratories International stock traded down $5.08 on Friday, reaching $241.34. 388,509 shares of the stock were exchanged, compared to its average volume of 553,307. The firm's 50 day moving average is $252.64 and its 200-day moving average is $219.95. Charles River Laboratories International, Inc. has a one year low of $161.65 and a one year high of $275.00. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.16 and a current ratio of 1.52. The firm has a market cap of $12.43 billion, a PE ratio of 26.20, a P/E/G ratio of 1.94 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 EPS for the quarter, beating the consensus estimate of $2.39 by $0.07. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $991.25 million. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The firm's revenue was down 7.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.98 EPS. As a group, analysts anticipate that Charles River Laboratories International, Inc. will post 11.01 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).